TABLE 2.
Strategy to enhance therapeutic efficacy of approved treatment through regulating ferroptosis in cancer.
| Treatment strategy | Treatment | Cancer type | Combination strategy to enhance treatment efficacy | References |
|---|---|---|---|---|
| Chemotherapy | Cisplatin | Ovarian cancer | CDDP + Erastin | Cheng et al. (2021) |
| PDAC | CDDP + DHA | Du et al. (2021) | ||
| Osteosarcoma | CDDP + Ursolic Acid | Zhen Tang et al. (2021) | ||
| Gemcitabine | Pancreatic cancer | Chrysin + Gemcitabine | Zhou et al. (2021) | |
| Doxorubicin | Osteosarcoma | Doxorubicin + Ferrate | Jingke Fu et al. (2021) | |
| Ovarian cancer | Doxorubicin + RSL3 | Gao et al. (2019a) | ||
| Targeted therapy | Cetuximab | KRAS mutant colorectal cancer | Cetuximab + RSL3 | Jiawen Yang et al. (2021) |
| Gefitinib | Triple negative breast cancer | Gefitinib + GPX4 Inhibition | Song et al. (2020) | |
| Everolimus | Renal cell carcinoma | Everolimus + Erastin/RSL3 | Yangyun et al. (2022) | |
| Sorafenib | HepG2 cell (hepatoellular carcinomas) | Dihydroartemisinin (DHA)+Sorafenib | Cui et al. (2022) | |
| Immunotherapy | PD-L1 blockade | Ovarian cancer | PD-L1 blockade + cyst(e)inase | Wang et al. (2019) |
| Multiple cancer types | PD-L1 blockade + Low-dose arachidonic acid | Liao et al. (2022) | ||
| Radiotherapy | Radiation | Lung adenocarcinoma, glioma | Radiation + Ferroptosis Inducers | Zeng Ye et al. (2020) |
| Melanoma | Ionizing radiation + ACSL3 KO/cyst(e)inase/SLC7A11 KO | Lang et al. (2019) |